Follow Us TR

News Details

Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

About Outlook Therapeutics, Inc.
  • NASDAQ: $OTLK
  • Notified: $0.78
  • 08:05 EDT

Price Chart